Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome binding/occupancy profiling of Zfp831-HA

ABSTRACT: Zfp831 is required for proper Tfh cell differentiation. In order to further understand the mechanisms whereby Zfp831 enhances Tfh differentiation, we conducted ChIP-seq analysis of Zfp831-HA

ORGANISM(S): Mus musculus

PROVIDER: GSE163734 | GEO | 2021/12/24

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Genome binding/occupancy profiling of Zfp831-HA

Project description:Genome binding/occupancy profiling of Zfp831-HA

| PRJNA687389 | ENA

Genome binding/occupancy profiling of Tox2 in Tfh-like cells

Project description:T Follicular helper (Tfh) cell is an effector CD4+ T cell subset specialized in helping B cells in germinal centers (GC) reactions. Although Bcl6 was identified as a Tfh-specific transcription factor essential for their development, the molecular mechanisms underlying Bcl6 regulation and Tfh cell commitment remain unclear. Here, we report that Tox2 transcription factor is highly expressed in Tfh cells, regulated by Bcl6 and STAT3. Forced expression of Tox2 drives Bcl6 expression and Tfh development. Mechanistically, Tox2 directly binds to Tfh-associated genes, including Bcl6, and functions to promote their chromatin accessibility and modulate the activities of other Tfh-regulating factors. Conversely, genetic deletion of Tox2 results in defective Tfh differentiation, and inhibiting both Tox and Tox2 in T cells abolishes Tfh differentiation and GC response. Thus, our results demonstrate that Tox2 is a key transcription factor that regulates Bcl6 expression and Tfh development and suggest a Tox2-Bcl6 axis in feed-forward regulation of Tfh program.

2019-10-30 | GSE136539 | GEO

Genome binding/occupancy profiling of Smad4 in Th17 cells cultured at 37°C and 39.5°C after 24 hours.

Project description:Smad4 was required for febrile temperature enhanced Th17 differentiation. In order to further understand the mechanisms whereby Smad4 enhance Th17 differentiation, we conducted ChIP-seq analysis of Smad4 in Th17 cells cutured 37°C and 39.5°C after 24 hours.

2020-06-26 | GSE125263 | GEO

Acinetobacter sp. HA strain:HA

Project description:Acinetobacter sp. HA strain:HA Genome sequencing and assembly

| PRJNA158435 | ENA

Labyrinthula sp. Ha isolate:Ha

Project description:Labyrinthula sp. Ha isolate:Ha Genome sequencing and assembly

| PRJNA607370 | ENA

miRNA array in the A549 Ago2-KO/HA-Ago2Wt, Ago2-KO/HA-Ago2KA, and Ago2-KO/HA-Ago2Δ (Dm) cells

Project description:We used miRNA microarrays to detail the miRNA content in A549 Ago2-KO/HA-Ago2Wt, Ago2-KO/HA-Ago2KA, and Ago2-KO/HA-Ago2Δ (Dm) cells

2024-04-18 | GSE255941 | GEO

Genome profiling of HA-hWDR5 binding in mouse embryonic bodies using SFEBq differetiation methods

Project description:This study describes the binding profile of HA-hWDR5 in mouse embryonic bodies with early (T12h) and late (T48h) rescue of HA-hWDR5

2019-11-21 | GSE116154 | GEO

HA-TFE3 bound regions in HK-2 HA-TFE3-inducible cells

Project description:TFE3 is a bHLH-ZIP transcription factor, which nuclear localization is regulated by a tumor suppressor FLCN. In order to analyze TFE3 occupancy in whole genome, we have generated and utilized a HK-2 HA-TFE3-inducible cell line which express HA-tagged TFE3 in a doxycycline-dependent manner. HA-TFE3 bound regions were determined by ChIPSeq.

2020-08-07 | GSE135490 | GEO

Trial of FOLF(HA)Iri With Cetuximab in mCRC

Project description:As an approach to improve efficacy and provide clinical benefit to cancer patients undergoing chemotherapeutic treatment regimens, Alchemia Oncology has developed a novel means for delivering anti-cancer agents to tumours. The drug delivery platform is based on the use of hyaluronic acid (HA), a novel excipient, in which, formulation with HA results in optimisation of cytotoxic drug uptake and retention within solid tumours. In the specific example of HA-Irinotecan, this new formulation of irinotecan has demonstrated enhanced efficacy in both nonclinical and early clinical studies. The current study is an investigation into the use of HA-Irinotecan in a Phase II single arm trial of FOLF(HA)iri plus cetuximab in irinotecan-naïve second line patients with KRAS wild type metastatic colorectal cancer. The study objectives are to confirm the safety and efficacy of FOLF(HA)iri plus cetuximab as second-line therapy in irinotecan-naïve metastatic colorectal cancer patients. It is expected that the study recruit approximately 40-50 patients in 1 year with subsequent treatment and follow up; thus the trial will run for approximately 2-3 years.

| 2172573 | ecrin-mdr-crc

Global gene expression profile of anti-CD3/CD28 or PMA/ionomycin stimulated CD4+ T cell, wild type and Mapk1-KO CD4+ T cells, and empty vector and sh-Zfp831 infected CD4+ T cells

Project description:Several factors promote Tfh cell differentiation. In order to understand how they promotes the expression of Tfh signature genes, we conducted transcriptional analysis.

2021-10-14 | GSE163702 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data